Sera Prognostics Reports Q2 2025 Financial Results

Sera Prognostics, Inc. ( (SERA) ) has released its Q2 earnings. Here is a breakdown of the information Sera Prognostics, Inc. presented to its investors.

Sera Prognostics, Inc., a health diagnostics company based in Salt Lake City, Utah, specializes in precision pregnancy care, offering innovative diagnostic tests to predict preterm birth risks and improve maternal and neonatal health outcomes.

In its second-quarter 2025 earnings report, Sera Prognostics highlighted ongoing progress in engaging Medicaid plans in states with high premature birth rates and announced leadership appointments to strengthen its commercial capabilities. The company is on track to publish full results of its PRIME study, which could demonstrate the health economic benefits of its PreTRM test.

Key financial metrics for the quarter included a slight decrease in revenue to $17,000 from $24,000 in the same period last year, while operating expenses remained flat at $9.3 million. The company reported a net loss of $8.0 million, a slight improvement from the $8.3 million loss in the previous year. Sera’s cash reserves, totaling approximately $108.5 million, are expected to support the company through significant commercial milestones until 2028.

Strategically, Sera Prognostics is focusing on expanding its market presence and preparing for anticipated revenue growth by investing in commercial activities and building market awareness. The recent appointments of Lee Anderson as Chief Commercial Officer, Chuck Hyde as Head of Market Access, and Jennifer Zibuda as Head of Investor Relations are pivotal to this strategy.

Looking ahead, Sera Prognostics remains committed to enhancing its commercial momentum and demonstrating the value of its PreTRM test in reducing premature births and healthcare costs, as it continues to engage with Medicaid and other healthcare organizations.